Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for uncontrolled asthma in adults with obesity
ACTRN12624001278527Phase 3Recruiting
- Sponsor
- Mater Misericordiae University Hospital
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tirzepatide in asthma and obesity, sponsored by Mater Misericordiae University Hospital. Primary endpoint: Asthma control at week 36. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
asthmaobesity
Beyond the preview
Go deeper on ACTRN12624001278527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001278527.